CIK 0000730272
- Large accelerated filer
REPLIGEN CORP
Sign in to watch- Ticker
- RGEN
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 042729386
- Phone
- +1 781-449-9560
- Business address
- 41 SEYON STREET, BUILDING 1, SUITE 100, WALTHAM, MA, 02453
- 4 Shares withheld for taxes See Remarks gave up 908 shares (to pay taxes)
- 4 Shares withheld for taxes Chief Operating Officer gave up 820 shares (to pay taxes)
- 4 Grant or award Chief Operating Officer acquired 8,691 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 19,719 shares (grant or award)
- 4 Grant or award Senior VP, R&D acquired 3,520 shares (grant or award)
- 4 Grant or award CFO acquired 2,540 shares (grant or award)
- 4 Grant or award President and CCO acquired 2,880 shares (grant or award)
- 4 Open-market sale Director sold 1,000 shares at $193.35 ($193,350)
- 4 Open-market sale Chief Operating Officer sold 4,373 shares at $198.08 ($866,204)
- 4/A Insider Changes in Ownership
- 4 Gift Chief Executive Officer gave 1,000 shares (gift)
- 4 Open-market sale See Remarks sold 3,788 shares at $147.13 ($557,328)
- 4 Grant or award President and CCO acquired 12,906 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Grant or award CFO acquired 5,503 shares (grant or award)
- 3 Insider Initial Statement of Ownership
- 4 Open-market sale Director sold 850 shares at $171.38 ($145,673)
- 4 Grant or award Director acquired 686 shares (grant or award)
- 4 Grant or award Director acquired 686 shares (grant or award)
- 4 Grant or award Director acquired 798 shares (grant or award)
Page 7 of 34 · 669 filings